GSK 2018682 / GSK - LARVOL DELTA

Repurposing GSK2018682 Confers Dual Antibacterial and Antibiofilm Activity against Staphylococcus aureus. (PubMed, ACS Infect Dis) - "In summary, our findings establish GSK2018682 as a promising anti-S. aureus agent with dual antibacterial and antibiofilm activities, acting through interaction with membrane phospholipids to disrupt membrane integrity and offering a strategy against resistant S. aureus infections."

Journal • Infectious Disease

Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: GlaxoSmithKline

Clinical • New P1 trial